TLDR A new compound, 3a, effectively fights prostate cancer better than finasteride.
The study focused on designing and synthesizing novel thiohydantoin derivatives as androgen receptor antagonists to treat prostate cancer. The di-cyanide analogues 3a-b and 3d demonstrated significant growth inhibition of androgen-sensitive LNCaP cells with IC50 values ranging from 2.64 to 20.62 µM. Hydrolyzing one cyanide group to an amide maintained activity, while conversion to an ester reduced it. Hydrophobic substitutions on the phenyl moiety improved predicted logP and growth inhibition. The study was self-funded and conducted by the authors without external financial support.
35 citations,
May 2020 in “Frontiers in Pharmacology” Different drugs for prostate-related urinary symptoms work but have various side effects, and treatment should be tailored to the individual.
19 citations,
October 2018 in “PLOS ONE” 5 alpha-reductase inhibitors can slightly improve symptoms of enlarged prostate but have a high risk of sexual side effects.
23 citations,
May 2019 in “Expert Opinion on Therapeutic Patents” New androgen receptor modulators show promise for treating diseases like prostate cancer and muscle wasting.
11 citations,
February 2016 in “Current Medicinal Chemistry” New treatments for prostate cancer and BPH show promise, including novel compounds that target hormone synthesis and response.
7 citations,
August 2019 in “Bioorganic & medicinal chemistry” Analog 23 is a promising compound for prostate cancer treatment.
204 citations,
February 2000 in “Current Medicinal Chemistry” Antiandrogens like flutamide are effective in treating conditions like prostate cancer and hair loss, but there's a need for more potent versions. Understanding their structure can help develop better treatments.
45 citations,
August 2005 in “Bioorganic & medicinal chemistry” New compounds with carborane showed anti-androgen effects similar to flutamide.